CorMedix Therapeutics: Communicable Diseases trials

The registry lists 13 Communicable Diseases studies with CorMedix Therapeutics as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 4Phase 3 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream InfectionCompletedNCT02651428Phase 3Results posted
• Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in AdultsCompletedNCT02168946Phase 3Results posted
• Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01984684Phase 3Results posted
• Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01811732Phase 3Results posted
• A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin InfectionsCompletedNCT01283581Phase 2Results posted
• Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionCompletedNCT01252732Phase 3Results posted
• Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)CompletedNCT01252719Phase 3Results posted
• Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin InfectionsCompletedNCT00719810Phase 2Results posted
• Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin InfectionsCompletedNCT00646958Phase 2Results posted
• A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World SettingCompletedNCT03160040
• A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World SettingCompletedNCT03159403
• Study of Cases of Serious Infections Due to Carbapenem-Resistant EnterobacteriaceaeCompletedNCT02420366
• A Study for Patients With Complicated Skin and Skin Structure InfectionsCompletedNCT00514527Phase 2